Immunotherapy for Cervical Cancer Info Update
The FDA
approved two new immunotherapy treatments for cervical cancer in 2021: the
antibody-drug conjugate tisotumab vedotin (Tivdak) and the checkpoint inhibitor
pembrolizumab (Keytruda). As the research and treatment landscape evolves, we
keep our information up to date.
No comments:
Post a Comment